ArticleRSC advances2026
PEG-GE11-modified nanoplatform for co-delivery of cisplatin and plumbagin in targeted therapy of oral squamous cell carcinoma.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study tackles key challenges in oral squamous cell carcinoma (OSCC) chemotherapy, such as poor targeting, systemic toxicity, and drug resistance. We developed a pH-responsive, targeted nanoplatform (CP@Cu-Z@P-G) based on copper-doped zeolitic imidazolate framework-8 (Cu-ZIF-8). The nanoplatform was functionalized with an Epidermal Growth Factor Receptor (EGFR)-specific ligand (PEG-GE11) for active tumor targeting and designed to degrade in the acidic tumor microenvironment, enabling the synchronous release of cisplatin (CDDP) and plumbagin (PLB). The released copper ions (Cu
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.